TIZIANA LIFE SCIENCES LTD (TLSA) Stock News

USA - NASDAQ:TLSA - BMG889121031 - Common Stock

1.76 USD

-0.06 (-3.3%)

Last: 9/23/2025, 8:16:27 PM

1.75 USD

-0.01 (-0.57%)

Pre-Market: 9/24/2025, 8:00:00 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TLSA Latest News, Press Relases and Analysis

All

Press Releases

43 minutes ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

43 minutes ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

9 days ago - By: Tiziana Life Sciences Ltd.

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

15 days ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

15 days ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

19 days ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Purchase of Shares by Chairman

19 days ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Purchase of Shares by Chairman

a month ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

a month ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

a month ago - By: Tiziana Life Sciences Ltd.

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

a month ago - By: Tiziana Life Sciences Ltd.

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

2 months ago - By: Benzinga - Mentions: UBER LCID TSLA

Lucid Is Now Shipping Adapters That Let Customers Access Elon Musk-Led Tesla's Supercharger Network

2 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

3 months ago - By: Benzinga - Mentions: ELVN HCTI SNES NCNA ...

12 Health Care Stocks Moving In Friday's Intraday Session

3 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

3 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

3 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences to Present at the Bio International Convention

3 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences to Present at the Bio International Convention

4 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

4 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

4 months ago - By: Tiziana Life Sciences Ltd.

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

5 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Purchase of Shares by Chairman

5 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

5 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

5 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

5 months ago - By: Yahoo Finance - Mentions: PHH ATPC MNPR AGL ...

Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025

5 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

5 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

6 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

6 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

6 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

6 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

6 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

6 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

7 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial